OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

CEO exercised or converted 4,542 RGEN derivative securities | OQRO

Home
Insider trades
Repligen
CEO exercised or converted 4,542 RGEN derivative securities

Insider trades

Insider trade

CEO exercised or converted 4,542 RGEN derivative securities

Traded Sep 24, 2026 · Filed Sep 26, 2026

RGERepligenRGEN

4,542
Shares · @ $155.38

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 24, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 26, 2026

CEOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001628280-26-063572

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Sep 26, 2026, 12:09 AM UTC

Added to OQRO

Oct 6, 2026, 8:46 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

REPLIGEN CORP

Issuer CIK

730272

Ticker

RGEN

Reporting person

Olivier Loeillot

Relationship

Director, Officer

Officer title

Chief Executive Officer

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Sep 24, 2026

Transaction code

Shares / units

4,542

Price per share

$155.38

Acquired / disposed

Acquired (A)

Shares owned after

52,911

Ownership form

Direct

Amendment

Footnotes from the filing

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Around the same time

Olivier Loeillot (Chief Executive Officer) sold ~$238K of Repligen

Scheduled in advanceFiled yesterday

Olivier LoeillotChief Executive Officer

Filed yesterday

4,202Shares · @ $154.96

Traded Oct 5 · filed 1 day later

Derivative exercise or conversion — not an open-market buy.

More Official record

Olivier Loeillot (Chief Executive Officer) sold ~$798K of Repligen

Scheduled in advanceFiled yesterday